|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・２・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
EP1690935A3
(en)
|
1990-01-12 |
2008-07-30 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5814318A
(en)
|
1990-08-29 |
1998-09-29 |
Genpharm International Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US7041871B1
(en)
|
1995-10-10 |
2006-05-09 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
GB9119338D0
(en)
|
1991-09-10 |
1991-10-23 |
Inst Of Animal Physiology And |
Control of gene expression
|
|
US5523226A
(en)
*
|
1993-05-14 |
1996-06-04 |
Biotechnology Research And Development Corp. |
Transgenic swine compositions and methods
|
|
US5512295A
(en)
|
1994-11-10 |
1996-04-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Synthetic liposomes for enhanced uptake and delivery
|
|
US6001349A
(en)
|
1995-02-22 |
1999-12-14 |
Therion Biologics Corporation |
Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US7001614B2
(en)
|
1996-08-19 |
2006-02-21 |
The United States Of America As Represented By The Department Of Health And Human Services |
Liposome complexes for increased systemic delivery
|
|
US6770291B2
(en)
|
1996-08-30 |
2004-08-03 |
The United States Of America As Represented By The Department Of Health And Human Services |
Liposome complexes for increased systemic delivery
|
|
EP1972194A1
(en)
|
1996-12-03 |
2008-09-24 |
Amgen Fremont Inc. |
Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
|
|
US7112338B2
(en)
|
1997-03-12 |
2006-09-26 |
The Regents Of The University Of California |
Cationic liposome delivery of taxanes to angiogenic blood vessels
|
|
US6235883B1
(en)
|
1997-05-05 |
2001-05-22 |
Abgenix, Inc. |
Human monoclonal antibodies to epidermal growth factor receptor
|
|
US6749863B1
(en)
|
1997-11-19 |
2004-06-15 |
Georgetown University |
Targeted liposome gene delivery
|
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
|
GB9823930D0
(en)
|
1998-11-03 |
1998-12-30 |
Babraham Inst |
Murine expression of human ig\ locus
|
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
US7105348B2
(en)
|
2000-10-31 |
2006-09-12 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
US6586251B2
(en)
|
2000-10-31 |
2003-07-01 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
US7795494B2
(en)
|
2001-03-22 |
2010-09-14 |
Abbott Laboratories |
Transgenic mice expressing antibodies specific for genes of interest and uses thereof
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
US8093357B2
(en)
|
2002-03-01 |
2012-01-10 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
US20090042291A1
(en)
|
2002-03-01 |
2009-02-12 |
Xencor, Inc. |
Optimized Fc variants
|
|
US8663622B2
(en)
|
2002-12-16 |
2014-03-04 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Recombinant vaccine viruses expressing IL-15 and methods using the same
|
|
US20060206949A1
(en)
|
2003-01-28 |
2006-09-14 |
Sylvain Arnould |
Custom-made meganuclease and use thereof
|
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
|
US8218805B2
(en)
|
2003-10-11 |
2012-07-10 |
Charles Hornback |
Wireless speaker system for use with ceiling fans
|
|
WO2005063815A2
(en)
|
2003-11-12 |
2005-07-14 |
Biogen Idec Ma Inc. |
Fcϝ receptor-binding polypeptide variants and methods related thereto
|
|
US20060034850A1
(en)
|
2004-05-27 |
2006-02-16 |
Weidanz Jon A |
Antibodies as T cell receptor mimics, methods of production and uses thereof
|
|
EP1802193B1
(en)
|
2004-10-19 |
2014-04-30 |
Regeneron Pharmaceuticals, Inc. |
Method for generating a mouse homozygous for a genetic modification
|
|
AU2005335714B2
(en)
|
2004-11-10 |
2012-07-26 |
Macrogenics, Inc. |
Engineering Fc antibody regions to confer effector function
|
|
US20060222653A1
(en)
|
2004-11-12 |
2006-10-05 |
Xencor, Inc. |
Antibodies operably linked to selected chemoattractants
|
|
CA2595169A1
(en)
|
2005-01-12 |
2006-07-20 |
Xencor, Inc. |
Antibodies and fc fusion proteins with altered immunogenicity
|
|
ES2347979T3
(es)
*
|
2005-08-03 |
2010-11-26 |
Therapeutic Human Polyclonals, Inc. |
Supresion de la apoptosis en linfocitos b en animales transgenicos que expresan inmunoglobulina humanizada.
|
|
EP1928495A2
(en)
|
2005-08-19 |
2008-06-11 |
Cerus Corporation |
Antibody-mediated enhancement of immune response
|
|
PL2578685T3
(pl)
|
2005-08-23 |
2020-01-31 |
The Trustees Of The University Of Pennsylvania |
Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania
|
|
JP5514539B2
(ja)
|
2006-03-31 |
2014-06-04 |
メダレックス・リミテッド・ライアビリティ・カンパニー |
ヒト抗体の調製に用いるためのキメラ抗体を発現するトランスジェニック動物
|
|
KR101703299B1
(ko)
|
2007-06-01 |
2017-02-06 |
오픈 모노클로날 테크놀로지, 인코포레이티드 |
내생적 면역글로불린 유전자를 억제하고 트랜스제닉 인간 이디오타입 항체를 생산하기 위한 방법 및 조성물
|
|
ES2608604T3
(es)
|
2007-10-18 |
2017-04-12 |
Bavarian Nordic A/S |
Uso de MVA para tratar el cáncer de próstata
|
|
US8225343B2
(en)
|
2008-01-11 |
2012-07-17 |
Sony Computer Entertainment America Llc |
Gesture cataloging and recognition
|
|
EP3456191A1
(en)
|
2008-06-27 |
2019-03-20 |
Merus N.V. |
Antibody producing non-human mammals
|
|
PL2346994T3
(pl)
|
2008-09-30 |
2022-04-19 |
Ablexis, Llc |
Myszy knock-in do wytwarzania chimerycznych przeciwciał
|
|
US8691502B2
(en)
|
2008-10-31 |
2014-04-08 |
Tremrx, Inc. |
T-cell vaccination with viral vectors via mechanical epidermal disruption
|
|
DK3241435T3
(da)
|
2009-07-08 |
2021-08-23 |
Kymab Ltd |
Dyremodeller og terapeutiske molekyler
|
|
RU2425880C2
(ru)
*
|
2009-07-30 |
2011-08-10 |
Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН |
Способ получения трансгенных мышей
|
|
WO2011072204A1
(en)
*
|
2009-12-10 |
2011-06-16 |
Regeneron Pharmaceuticals, Inc. |
Mice that make heavy chain antibodies
|
|
US20130185821A1
(en)
|
2010-02-08 |
2013-07-18 |
Regeneron Pharmaceuticals, Inc. |
Common Light Chain Mouse
|
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
|
US20120021409A1
(en)
*
|
2010-02-08 |
2012-01-26 |
Regeneron Pharmaceuticals, Inc. |
Common Light Chain Mouse
|
|
US20130045492A1
(en)
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
|
SG183149A1
(en)
|
2010-02-08 |
2012-09-27 |
Regeneron Pharma |
Common light chain mouse
|
|
US20130108623A1
(en)
|
2010-03-29 |
2013-05-02 |
Zymeworks Inc |
Antibodies with Enhanced or Suppressed Effector Function
|
|
PL3248462T3
(pl)
|
2010-03-31 |
2024-07-08 |
Ablexis, Llc |
Modyfikacja myszy metodami inżynierii genetycznej w celu wytworzenia przeciwciał chimerycznych
|
|
MY195217A
(en)
|
2010-06-22 |
2023-01-11 |
Regeneron Pharma |
MICE Expressing An Immunoglobulin Hybrid Light Chain
|
|
CN103025884B
(zh)
|
2010-07-26 |
2015-11-25 |
特里安尼公司 |
转基因动物和使用方法
|
|
EP2601298B1
(en)
|
2010-08-02 |
2016-11-30 |
Regeneron Pharmaceuticals, Inc. |
Mice that make binding proteins comprising vl domains
|
|
CN105861548B
(zh)
|
2011-02-25 |
2020-01-10 |
瑞泽恩制药公司 |
Adam6小鼠
|
|
JP5893258B2
(ja)
|
2011-03-31 |
2016-03-23 |
フェリカネットワークス株式会社 |
情報処理装置および方法、並びにプログラム
|
|
US20130018582A1
(en)
|
2011-07-13 |
2013-01-17 |
Miller Paul A |
Inertial Navigation Common Azimuth Reference Determination System and Method
|
|
ES2872081T3
(es)
|
2011-08-05 |
2021-11-02 |
Regeneron Pharma |
Ratones con cadena ligera universal humanizada
|
|
AU2012311286B2
(en)
*
|
2011-09-19 |
2018-07-26 |
Kymab Limited |
Antibodies, variable domains and chains tailored for human use
|
|
CA2791109C
(en)
|
2011-09-26 |
2021-02-16 |
Merus B.V. |
Generation of binding molecules
|
|
EP4074833A1
(en)
|
2011-10-17 |
2022-10-19 |
Regeneron Pharmaceuticals, Inc. |
Restricted immunoglobulin heavy chain mice
|
|
KR102295746B1
(ko)
|
2011-10-28 |
2021-09-01 |
리제너론 파아마슈티컬스, 인크. |
유전자 변형된 주요 조직적합성 복합체 마우스
|
|
US9043996B2
(en)
|
2011-10-28 |
2015-06-02 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified major histocompatibility complex animals
|
|
RS61455B1
(sr)
*
|
2011-10-28 |
2021-03-31 |
Regeneron Pharma |
Genetski modifikovani miševi t ćelijskog receptora
|
|
RS63220B1
(sr)
|
2011-10-28 |
2022-06-30 |
Regeneron Pharma |
Genetski modifikovani miševi sa ekspresijom himernih molekula klase ii glavnog kompleksa histokompatibilnosti (mhc)
|
|
US9591835B2
(en)
|
2011-10-28 |
2017-03-14 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified major histocompatibility complex animals
|
|
SI2818478T1
(sl)
|
2011-10-28 |
2017-07-31 |
Regeneron Pharmaceuticals, Inc. |
Humanizirani il-6 in receptor il-6
|
|
US9574010B2
(en)
|
2011-11-04 |
2017-02-21 |
Zymeworks Inc. |
Stable heterodimeric antibody design with mutations in the Fc domain
|
|
US9120662B2
(en)
|
2011-11-14 |
2015-09-01 |
Susan A. Thomson |
Gathering and dispensing scoop with gate valve
|
|
US9547499B2
(en)
|
2011-12-09 |
2017-01-17 |
Microsoft Technology Licensing, Llc |
Device configuration with cached pre-assembled driver state
|
|
US20140013456A1
(en)
|
2012-03-16 |
2014-01-09 |
Regeneron Pharmaceuticals, Inc. |
Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
|
|
US9801362B2
(en)
|
2012-03-16 |
2017-10-31 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals expressing pH-sensitive immunoglobulin sequences
|
|
HUE037659T2
(hu)
|
2012-03-16 |
2018-09-28 |
Regeneron Pharma |
Hisztidinmódosított könnyûlánc antitestek és genetikailag módosított rágcsálók ennek az elõállítására
|
|
WO2013138681A1
(en)
*
|
2012-03-16 |
2013-09-19 |
Regeneron Pharmaceuticals, Inc. |
Mice that produce antigen-binding proteins with ph-dependent binding characteristics
|
|
JP5920830B2
(ja)
|
2012-09-28 |
2016-05-18 |
シスメックス株式会社 |
試料調製装置および細胞分析装置
|
|
WO2014093908A2
(en)
|
2012-12-14 |
2014-06-19 |
Omt, Inc. |
Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same
|
|
US9848587B2
(en)
|
2013-02-20 |
2017-12-26 |
Regeneron Pharmaceuticals, Inc. |
Humanized T cell co-receptor mice
|
|
RS57582B1
(sr)
|
2013-02-20 |
2018-11-30 |
Regeneron Pharma |
Nehumane životinje sa modifikovanim sekvencama imunoglobulinskog teškog lanca
|
|
SI2958937T1
(sl)
|
2013-02-22 |
2018-12-31 |
Regeneron Pharmaceuticals, Inc. |
Miš, ki izraža humanizirani poglavitni histokompatibilnostni kompleks
|
|
DK3456831T3
(da)
|
2013-04-16 |
2021-09-06 |
Regeneron Pharma |
Målrettet modifikation af rottegenom
|
|
US9783618B2
(en)
*
|
2013-05-01 |
2017-10-10 |
Kymab Limited |
Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
|
|
MX388127B
(es)
|
2013-12-11 |
2025-03-19 |
Regeneron Pharma |
Metodos y composiciones para la modificacion dirigida de un genoma.
|
|
AU2015230938C1
(en)
|
2014-03-21 |
2021-10-14 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that make single domain binding proteins
|
|
SG10201808083VA
(en)
|
2014-03-21 |
2018-10-30 |
Regeneron Pharma |
Vl antigen binding proteins exhibiting distinct binding characteristics
|
|
DK3152312T3
(da)
|
2014-06-06 |
2020-04-06 |
Regeneron Pharma |
Fremgangsmåder og sammensætninger til modifikation af et mållocus
|
|
WO2015196051A1
(en)
*
|
2014-06-19 |
2015-12-23 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having a humanized programmed cell death 1 gene
|
|
US9738897B2
(en)
|
2014-06-23 |
2017-08-22 |
Regeneron Pharmaceuticals, Inc. |
Nuclease-mediated DNA assembly
|
|
DK3161128T3
(en)
|
2014-06-26 |
2018-11-05 |
Regeneron Pharma |
METHODS AND COMPOSITIONS FOR TARGETED GENTICAL MODIFICATIONS AND PROCEDURES FOR USE THEREOF
|
|
US20160081314A1
(en)
*
|
2014-09-19 |
2016-03-24 |
Regeneron Pharmaceuticals, Inc. |
Chimeric Antigen Receptors
|
|
MX2017012829A
(es)
|
2015-04-06 |
2018-02-23 |
Regeneron Pharma |
Respuestas inmunitarias mediadas por células t humanizadas en animales no humanos.
|
|
CN109640644B
(zh)
|
2016-06-03 |
2021-10-26 |
瑞泽恩制药公司 |
表达外源末端脱氧核苷酸转移酶的非人动物
|